| Term 
 | Definition 
 
        | -the concentration at which half the receptors have ligand bound   Kd=[L][R]/[LR] |  | 
        |  | 
        
        | Term 
 
        | Graded Dose Effect Relationships |  | Definition 
 
        | -the response to a drug is proportional to the concentrationof receptors that have drug bound to them   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | -concentration at which a half-maximal effect is obtained -a measure of potency 
 -EC50 may or may not equal Kd     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | compounds that promote the conformational change to an active receptor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | bind to the receptor but do not promote the conformational change |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | -activation of an opposing physiological mechanism to reduce an undesirable response or state -ex) vasoconstrict nasal mucosa with psuedoephedrine to contract vasodilation caused by histamine -compensatory pathway |  | 
        |  | 
        
        | Term 
 
        | Pharmacological antagonist |  | Definition 
 
        | interact directly with the target for the endogenous ligand |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | -binds reversibly to the active site but does not induce a conformational change -increases EC50 therefore decrease the potency -no effect on maximal efficacy       |  | 
        |  | 
        
        | Term 
 
        | Noncompetitive Antagonist |  | Definition 
 
        | -either binds irreversibly to active site or reversibly to an allostertic site -decrease the efficacy -EC50 does not change |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | -binds to agonist binding site, but even when the receptors are fully occupied, they have a lower efficacy -full and partial agonists bind to the same site but with different efficacies -therefore, a partial agonist will reduce the effect of a full agonist, appearing as a competitive antagonist -rather than completely inhibiting the response to a full agonist, one will see a reduction to a level of activity equal to the efficacy of the partial agonist -used as a competitive antagonist with a built-in safe margin so that an overdose will not completely reduce activity |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | -in some cases, a receptor can be active in the absence of an agonist -acts by inhibiting this constitutive activity of the unoccupied receptor -deactivates receptors that are active in the absence of agonists   -there will be situations where the antagonist will have no effect(bc there is not agonist at the receptor -inverse agonist will have an effect (bc the receptor is constitutively turned on)     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | -We assume that the max effect is seen when 100% of receptors are bound (this is not the case) -the maximal effect is obtained at a lower dose than is required for receptor saturation -EC50<Kd -due to the fact that various signal transduction pathways activated by drugs allow for significant amplification of a relatively small signal |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | median effective dose to produce therapeutic response |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | median dose to produce toxic reponse |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | median dose to kill subjects |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | TD50/ED50 -the greater the therapeutic windo, the better margin of safety |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | LD1/ED99 the bigger the better |  | 
        |  |